FDA Brief

Warning letters Drugs

FDA warning letter to

Colgin, Inc.

High riskIssued Jan 25, 2024Posted Mar 5, 2024Division of Pharmaceutical Quality Operations II

FDA warned Colgin that its OTC drug ChigaRid External Analgesic violated manufacturing quality rules, including expired ingredients and missing tests.

What happened

FDA inspected Colgin’s Dallas drug manufacturing facility from September 18 to September 21, 2023. FDA found that Colgin did not test incoming components for identity, relied on supplier certificates of analysis (COAs) without establishing their reliability, used expired raw materials, had not validated its manufacturing process, and lacked adequate quality-unit oversight over microbiological testing, investigations, cleaning, stability, product reviews, and training. Colgin’s September 28, 2023, response was inadequate.

What FDA found

  1. Colgin did not test each incoming component for identity before use and did not establish the reliability of suppliers' test results; it also approved expired raw materials for production.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  2. Colgin had not validated the manufacturing process for ChigaRid External Analgesic.

    21 CFR 211.100(a)
  3. Colgin’s quality unit did not ensure adequate microbiological testing and specifications for finished drug products.

    21 CFR 211.22 and 211.165(b)
  4. Colgin’s quality unit did not ensure thorough investigations of batch discrepancies or failures to meet specifications.

    21 CFR 211.22 and 211.192
  5. Colgin’s quality unit did not ensure adequate cleaning and maintenance of dedicated manufacturing equipment.

    21 CFR 211.22 and 211.67(a)
  6. Colgin’s quality unit did not ensure an adequate stability program, annual product reviews, or adequate employee training.

    21 CFR 211.22, 211.137(a), 211.180(e), and 211.25(a)

What FDA wants

FDA tells Colgin to respond in writing within 15 working days with corrective actions and supporting documents, including a materials-system review, process validation plan, and quality-unit remediation plan. FDA also recommends a qualified CGMP consultant.

Who should pay attention

  • OTC drug brands that use contract manufacturers
  • contract manufacturers of finished drug products
  • quality teams managing supplier qualification and process validation

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk